Skip to main content

Table 1 Characteristics of included studies

From: Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Trial Phase SMO inhibitor Sample size No. of MB patients Disease stage Endpoints
LoRusso 2011 I Vismodegib 68 1 Refractory Safety and tumor responses
Gajjar 2013 I Vismodegib 33 33 Refractory or relapsed Safety and tumor responses
Rodon 2014 I Sonidegib 103 9 Relapsed Safety and tumor responses
Robinson 2015 II Vismodegib 40 40 Refractory or recurrent Safety and tumor responses
Kieran 2017 I and II Sonidegib 76 55 Phase I: Progressed
Phase II: Recurrent or relapsed
Safety and tumor responses